Your browser doesn't support javascript.
loading
Mutations in TP53, PIK3CA, PTEN and other genes in EGFR mutated lung cancers: Correlation with clinical outcomes.
VanderLaan, Paul A; Rangachari, Deepa; Mockus, Susan M; Spotlow, Vanessa; Reddi, Honey V; Malcolm, Joan; Huberman, Mark S; Joseph, Loren J; Kobayashi, Susumu S; Costa, Daniel B.
Afiliação
  • VanderLaan PA; Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States.
  • Rangachari D; Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States.
  • Mockus SM; The Jackson Laboratory for Genomic Medicine, Farmington, CT, United States.
  • Spotlow V; The Jackson Laboratory for Genomic Medicine, Farmington, CT, United States.
  • Reddi HV; The Jackson Laboratory for Genomic Medicine, Farmington, CT, United States.
  • Malcolm J; The Jackson Laboratory for Genomic Medicine, Farmington, CT, United States.
  • Huberman MS; Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States.
  • Joseph LJ; Department of Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States.
  • Kobayashi SS; Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States.
  • Costa DB; Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, United States. Electronic address: dbcosta@bidmc.harvard.edu.
Lung Cancer ; 106: 17-21, 2017 04.
Article em En | MEDLINE | ID: mdl-28285689
ABSTRACT

INTRODUCTION:

The degree and duration of response to epidermal growth factor receptor (EGFR) inhibitors in EGFR mutated lung cancer are heterogeneous. We hypothesized that the concurrent genomic landscape of these tumors, which is currently unknown in view of the prevailing single gene assay diagnostic paradigm in clinical practice, could play a role in clinical outcomes and/or mechanisms of resistance.

METHODS:

We retrospectively probed our institutional lung cancer database for tumors with EGFR kinase domain mutations that were also evaluated by more comprehensive molecular profiling, and evaluated tumor response to EGFR tyrosine kinase inhibitors (TKIs).

RESULTS:

Out of 171 EGFR mutated tumor-patient cases, 20 were sequenced using at least a limited comprehensive genomic profiling platform. 50% harbored concurrent TP53 mutation, 10% PIK3CA mutation, 5% PTEN mutation, among others. The response rate to EGFR TKIs, the median progression-free survival (PFS) to TKIs, the percentage of EGFR-T790M TKI resistance and survival had higher trends in EGFR mutant/TP53 wild-type cases when compared to EGFR mutant/TP53 mutant tumors (all p >0.05 without statistical significance); with a significantly longer median PFS in EGFR-exon 19 deletion mutant/TP53 wild-type cancers treated with 1st generation EGFR TKIs (p=0.035).

CONCLUSIONS:

Concurrent mutations, specifically TP53, are common in EGFR mutated lung cancer and may alter clinical outcomes. Additional cohorts will be needed to determine if comprehensive molecular profiling adds clinically relevant information to single gene assay identification in oncogene-driven lung cancers.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteína Supressora de Tumor p53 / PTEN Fosfo-Hidrolase / Classe I de Fosfatidilinositol 3-Quinases / Receptores ErbB / Neoplasias Pulmonares / Mutação Tipo de estudo: Observational_studies / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteína Supressora de Tumor p53 / PTEN Fosfo-Hidrolase / Classe I de Fosfatidilinositol 3-Quinases / Receptores ErbB / Neoplasias Pulmonares / Mutação Tipo de estudo: Observational_studies / Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2017 Tipo de documento: Article